Amendments to the Claims

The following listing of claims replaces all prior listings and versions of claims in the application.

1. (currently amended) A method of treating a human patient ~~an animal~~ with cancer who has received an allogeneic hematopoietic cell transplant, comprising administering to said animal an amount of beclomethasone 17,21-dipropionate ~~oral topically active corticosteroid~~ effective to prevent or reduce symptoms of GVHD while maintaining a GVL reaction effective to eliminate or reduce the number of cancer cells in the blood of said animal.

2. – 3. (cancelled)

4. (currently amended) The method of claim 1, wherein the beclomethasone 17,21-dipropionate ~~topically active corticosteroid~~ is administered orally at a dosage of between about 0.1 mg per day to about 8 mg per day.

5. (currently amended) The method of claim 1 wherein the beclomethasone 17,21-dipropionate ~~topically active corticosteroid~~ is administered orally at a dosage of between about 2 mg per day to about 4 mg per day.

6. (currently amended) The method of claim 1 wherein the beclomethasone 17,21-dipropionate ~~topically active corticosteroid~~ is administered orally from day 1 to about day 80 following hematopoietic cell transplantation.

7. (currently amended) The method of claim 1 wherein the beclomethasone 17,21-dipropionate ~~topically active corticosteroid~~ is administered in combination with prednisone or prednisolone at a concentration of at least 1 mg/kg body weight/day.

8. (currently amended) The method of claim 1 wherein the beclomethasone 17,21-dipropionate ~~topically active corticosteroid~~ is formulated for oral administration in the form of a pill, tablet, capsule or microsphere.

9. (currently amended) The method of claim 8 wherein the beclomethasone 17,21-dipropionate ~~topically active corticosteroid~~ is formulated such that the pill, microsphere, or capsule dissolves in the stomach, small intestine or colon.

10. (currently amended) The method of claim 1 wherein the beclomethasone 17,21-dipropionate ~~topically active corticosteroid~~ is formulated for oral administration in the form of an emulsion.

11. (currently amended) The method of claim 1 wherein said beclomethasone 17,21-dipropionate ~~topically active corticosteroid~~ is administered following infusion of the hematopoietic cells.

12. (currently amended) The method of claim 1 wherein administration of the beclomethasone 17,21-dipropionate ~~topically active corticosteroid~~ ceases after 80 days following infusion of the hematopoietic cells.

13. (original) The method of claim 1 wherein the patient has received an allogeneic bone marrow transplant.

14. (original) The method of claim 1 wherein the patient has received an allogeneic blood transplant.

15. (currently amended) The method of claim 1 wherein the beclomethasone 17,21-dipropionate ~~topically active corticosteroid~~ is administered in combination with at least one of cyclosporine, methotrexate, tacrolimus, anti-lymphocyte globulin, anti-T-cell monoclonal antibodies and anti-T-cell immunotoxins.

16. – 18. (cancelled)